A pilot study: Metabolic profiling of plasma and saliva samples from newly diagnosed glioblastoma patients
Cancer Medicine · 2023-05 · 12 (10) · 11427-11437
DOI: 10.1002/cam4.5857 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 09.04.2023. Verfasst von Juliana Muller Bark und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Health, Centre for Biomedical Technologies, School of Biomedical Sciences, Queensland University of Technology, Brisbane, Queensland, Aust…. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Royal Brisbane and Women's Hospital Foundation, Cancer Australia, Cure Brain Cancer Foundation.
Abstract (Originalsprache)
Background
Despite aggressive treatment, more than 90% of glioblastoma (GBM) patients experience recurrences. GBM response to therapy is currently assessed by imaging techniques and tissue biopsy. However, difficulties with these methods may cause misinterpretation of treatment outcomes. Currently, no validated therapy response biomarkers are available for monitoring GBM progression. Metabolomics holds potential as a complementary tool to improve the interpretation of therapy responses to help in clinical interventions for GBM patients.
Methods
Saliva and blood from GBM patients were collected pre and postoperatively. Patients were stratified conforming their progression‐free survival (PFS) into favourable or unfavourable clinical outcomes (>9 months or PFS ≤ 9 months, respectively). Analysis of saliva (whole‐mouth and oral rinse) and plasma samples was conducted utilising LC‐QqQ‐MS and LC‐QTOF‐MS to determine the metabolomic and lipidomic profiles. The data were investigated using univariate and multivariate statistical analyses and graphical LASSO‐based graphic network analyses.
Results
Altogether, 151 metabolites and 197 lipids were detected within all saliva and plasma samples. Among the patients with unfavourable outcomes, metabolites such as cyclic‐AMP, 3‐hydroxy‐kynurenine, dihydroorotate, UDP and cis‐aconitate were elevated, compared to patients with favourable outcomes during pre‐and post‐surgery. These metabolites showed to impact the pentose phosphate and Warburg effect pathways. The lipid profile of patients who experienced unfavourable outcomes revealed a higher heterogeneity in the abundance of lipids and fewer associations between markers in contrast to the favourable outcome group.
Conclusion
Our findings indicate that changes in salivary and plasma metabolites in GBM patients can potentially be employed as less invasive prognostic biomarkers/biomarker panel but validation with larger cohorts is required.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Health, Centre for Biomedical Technologies, School of Biomedical Sciences, Queensland University of Technology, Brisbane, Queensland, Australia.
- Saliva and Liquid Biopsy Translational Laboratory, Griffith Institute for Drug Discovery - Griffith University, Brisbane, Queensland, Australia.
- Faculty of Health, School of Biomedical Sciences, Queensland University of Technology, Gardens Point, Queensland, Australia.
- Environment, Commonwealth Scientific and Industrial Research Organization (CSIRO), Ecosciences Precinct, Dutton Park, Queensland, Australia.
- Agriculture and Food, Commonwealth Scientific and Industrial Research Organization (CSIRO), Acton, Australian Capital Territory, Australia.
- Australian eHealth Research Centre, CSIRO. Level 7, Surgical Treatment and Rehabilitation Service - STARS, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.
ORCID-Profile: Juliana Muller Bark, Chamindie Punyadeera
Förderung
- Royal Brisbane and Women's Hospital Foundation
- Cancer Australia
- Cure Brain Cancer Foundation
Zitieren
APA
Muller Bark, J., Karpe, A. V., Doecke, J. D., Leo, P., Jeffree, R. L., Chua, B., Day, B. W., Beale, D. J., & Punyadeera, C. (2023). A pilot study: Metabolic profiling of plasma and saliva samples from newly diagnosed glioblastoma patients. Cancer Medicine, 12(10), 11427-11437. https://doi.org/10.1002/cam4.5857
Vancouver
Muller Bark J, Karpe AV, Doecke JD, Leo P, Jeffree RL, Chua B, et al. A pilot study: Metabolic profiling of plasma and saliva samples from newly diagnosed glioblastoma patients. Cancer Medicine. 2023;12(10):11427-11437. doi:10.1002/cam4.5857
BibTeX
@article{MullerBark2023,
author = {Muller Bark, Juliana and Karpe, Avinash V and Doecke, James D and Leo, Paul and Jeffree, Rosalind L and Chua, Benjamin and Day, Bryan W and Beale, David J and Punyadeera, Chamindie},
title = {A pilot study: Metabolic profiling of plasma and saliva samples from newly diagnosed glioblastoma patients},
journal = {Cancer Medicine},
year = {2023},
volume = {12},
number = {10},
pages = {11427--11437},
doi = {10.1002/cam4.5857}
}
EUVIMED